ESTELA‐Study: Long‐Term Effectiveness and Safety of Anti‐Calcitonin Gene‐Related Peptide Monoclonal Antibodies in Real‐World Clinical Practice
Brain and Behavior · 2026-06 · 16 (6)
DOI: 10.1002/brb3.71560 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift Brain and Behavior, online erschienen am 25.06.2026. Verfasst von Alba Somovilla und 28 weiteren Autor:innen. Beteiligte Einrichtung: Headache Unit, Department of Neurology, Health Research Institute, La Princesa University Hospital, Madrid, Spain. Hauptthemen laut MEDLINE: Migraine Disorders, Calcitonin Gene-Related Peptide, Antibodies, Monoclonal, Antibodies, Monoclonal, Humanized. Die Arbeit nennt 36 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Instituto de Salud Carlos III (ISCIII), European Regional Development Fund (ERDF), IMPaCT project:, Next Generation EU.
Abstract (Originalsprache)
Background
Anti‐CGRP antibodies are effective and safe in real‐world migraine management, but guidelines recommend discontinuation after 12–18 months due to limited long‐term data and remaining uncertainties regarding optimal treatment duration and sustained safety, highlighting the need for large‐scale long‐term real‐world evidence. This study evaluated their safety and effectiveness in patients treated for ≥2 years.
Methods
This multicenter retrospective study included patients from 13 headache units who received the same anti‐CGRP antibody for ≥24 months, excluding discontinuation periods. Baseline characteristics, monthly headache days (MHD), monthly migraine days (MMD), and adverse events (AEs) were recorded at baseline, 6 months, 1, 2, 3, and 4 years. Descriptive statistics were used to summarize clinical characteristics, and appropriate parametric or non‐parametric tests were applied for group comparisons. Multivariate analyses were performed to explore associations between baseline variables and long‐term treatment response.
Results
A total of 454 patients (91% female, mean age 48) were analyzed, with follow‐up at 2 years ( n = 454), 3 years ( n = 135), and 4 years ( n = 17). Treatments included erenumab (39%), galcanezumab (34%), and fremanezumab (27%). Fifty‐seven percent maintained continuous therapy, while 43% restarted after discontinuation. Sustained reductions in MHD and MMD were observed at 2, 3, and 4 years (MHD from 20 to 6, 6, 5/MMD from 14 to 4, 4, and 2). Medication overuse decreased from 78% to 13%, 20%, and 18%. Loss of effectiveness occurred in 4.2% after 2 years. AEs appeared in 80%), leading to discontinuation in 0.4%. Multivariate analysis showed that shorter disease duration prior to anti‐CGRP initiation, earlier anti‐CGRP initiation, and greater MHD/MMD reduction at 6 months were associated with better long‐term outcomes.
Conclusions
Anti‐CGRP mAbs demonstrate sustained long‐term safety and effectiveness, with consistent reduction in headache and migraine days and lower medication overuse. Early initiation and greater initial improvement predict better long‐term outcomes. Findings support extending therapy beyond 12–18 months, supporting optimization of clinical protocols.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Headache Unit, Department of Neurology, Health Research Institute, La Princesa University Hospital, Madrid, Spain.
- Electronic Engineering Department, Universidad Politécnica de Madrid, Madrid, Spain.
- CCS: Center for Computational Simulation, Universidad Politécnica de Madrid, Madrid, Spain.
- Headache Unit, Department of Neurology, Health Research Institute (IdiPAZ), La Paz University Hospital, Madrid, Spain.
- Headache Unit, Department of Neurology, Fuenlabrada University Hospital, Madrid, Spain.
- Headache Unit, Department of Neurology, Health Research Institute, Clínico San Carlos Hospital, Madrid, Spain.
ORCID-Profile: Alba Somovilla, Iris Fernández-Lázaro, Ana Gago-Veiga
Förderung
- Instituto de Salud Carlos III (ISCIII)
- European Regional Development Fund (ERDF), IMPaCT project:
- Next Generation EU
- European Union
- European Commission
Zitieren
APA
Somovilla, A., Fernández-Lázaro, I., Pagán, J., Saiz, D., Díaz-De-Terán, J., Portocarrero Sánchez, L., Latorre, G., Calle De Miguel, C., González-García, N., Cuadrado, M. L., Porta-Etessam, J., Casas-Limón, J., Garcia-Azorin, D., Guerrero-Peral, Á., González-Osorio, Y., Gonzalez-Martinez, A., Martín Ávila, G., Terrero Carpio, R., Rodríguez-Vico, J., …, & Gago-Veiga, A. (2026). ESTELA‐Study: Long‐Term Effectiveness and Safety of Anti‐Calcitonin Gene‐Related Peptide Monoclonal Antibodies in Real‐World Clinical Practice. Brain and Behavior, 16(6). https://doi.org/10.1002/brb3.71560
Vancouver
Somovilla A, Fernández-Lázaro I, Pagán J, Saiz D, Díaz-De-Terán J, Portocarrero Sánchez L, et al. ESTELA‐Study: Long‐Term Effectiveness and Safety of Anti‐Calcitonin Gene‐Related Peptide Monoclonal Antibodies in Real‐World Clinical Practice. Brain and Behavior. 2026;16(6). doi:10.1002/brb3.71560
BibTeX
@article{Somovilla2026,
author = {Somovilla, Alba and Fernández-Lázaro, Iris and Pagán, Josué and Saiz, Daniel and Díaz-De-Terán, Javier and Portocarrero Sánchez, Leonardo and Latorre, Germán and Calle De Miguel, Carlos and González-García, Nuria and Cuadrado, María-Luz and Porta-Etessam, Jesús and Casas-Limón, Javier and Garcia-Azorin, David and Guerrero-Peral, Ángel and González-Osorio, Yésica and Gonzalez-Martinez, Alicia and Martín Ávila, Guillermo and Terrero Carpio, Rodrigo and Rodríguez-Vico, Jaime and Jaimes, Alex and Gómez García, Andrea and Trevino-Peinado, Cristina and Sanchez-Del-Rio, Margarita and Lozano Ros, Alberto and Sánchez-Soblechero, Antonio and Urtiaga Valle, Sarai and González-Salaices, Marta and Riva, Elena and Gago-Veiga, Ana},
title = {ESTELA‐Study: Long‐Term Effectiveness and Safety of Anti‐Calcitonin Gene‐Related Peptide Monoclonal Antibodies in Real‐World Clinical Practice},
journal = {Brain and Behavior},
year = {2026},
volume = {16},
number = {6},
doi = {10.1002/brb3.71560}
}
EUVIMED